Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib vs Gefitinib in advanced NSCLC
NCT01040780Phase 3Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Feb 2009
- Primary completion
- Mar 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Feb 2009; status: completed.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01040780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01040780.